Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Combination Cancer Immunotherapy Market Opportunities to 2028 - Featuring Abbvie, Amgen and Eli Lilly Among Others -

June 23, 2022 GMT

DUBLIN--(BUSINESS WIRE)--Jun 23, 2022--

The “Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028” report has been added to’s offering.

As per report findings, the global combinational immunotherapy market is expected to surpass US$ 15 Billion by 2028. This is mainly attributed to the rising geriatric population and a surge in the prevalence of various cancers. This possesses high medical needs for the development of targeted therapies in its management.

In addition, rising investments by pharmaceutical companies due to the promising response of combinational immunotherapy is also driving the growth of the market.

In recent years, cancer immunotherapy has emerged as an appealing strategy for overcoming the limitations of conventional therapies. The novel therapy aims to harness the ability of the immune system to recognize, target, and destroy cancer cells.


Cancer immunotherapy now encompasses several therapeutic agents including monoclonal antibodies, immune checkpoint inhibitors, vaccines, antibody-drug conjugates, and others. All these novel approaches have their distinct target and mechanism of action.

Although immunotherapies have shown significant improvement in the clinical outcomes of cancer patients, these are associated with several limitations. Tumor heterogeneity and the development of resistance are the major challenges to current immunotherapeutic approaches.

This has pushed the research studies to evaluate immunotherapy in combination with other cancer-targeting approaches including chemotherapy, radiotherapy, targeted drugs, and other immunotherapeutic approaches. Combination therapy aims to combine two or more drugs that have a synergistic mechanism of action in targeting the disease.

In comparison to monotherapy, combinational therapy aims to have a more enhanced and additive effect in the targeting of cancer cells. Further, it also has the potential to overcome drug resistance and enhance the overall survival rate in cancer patients. The conferred advantages associated with combinational therapies have drawn the interest of several pharmaceutical giants to invest in this segment.

Currently, several drugs such as Opdivo, Yervoy, Bevacizumab, and others have gained approval as combinational immunotherapy for the management of cancer cells In 2022, US FDA has granted approval to the fixed-dose combination of relatlimab (LAG-3 inhibitor) plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma. The novel combination has shown manageable safety with no new or unexpected safety signals. The combination is sold under the trade name Opdualag and is marketed by Bristol Myers Squibb.

In the last few years, pharmaceutical companies have begun to embrace a more collaborative way of working to mitigate the obstacles of drug development. The manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge, and expand the business.


Companies Mentioned

  • Abbvie
  • Agenus
  • Akeso Pharmaceutical
  • Amgen
  • Arbutus Biopharma
  • Astrazeneca
  • Aum Bioscience
  • Beigene
  • Biontech
  • Bristol Myers Squibb
  • Candel Therapeutics
  • Eli Lilly
  • Elicio Therapeutics
  • Fate Therapeutics
  • GlaxoSmithKline
  • Harpoon Therapeutics
  • Immutep
  • Imugene
  • Intensity Therapeutics
  • Janssen Pharmaceuticals
  • Merck
  • Morphosys
  • Novartis
  • Novocure
  • Nykode Therapeutics
  • Ono Pharmaceutical
  • Oxford Biotherapeutics
  • Pfizer
  • Qurient
  • Regeneron
  • Roche
  • Sanofi
  • Seagen
  • Shanghai Junshi Biosciences
  • Takeda Pharmaceuticals

Report Highlights:

  • Global and Regional Combination Cancer Immunotherapy Market Insight Till 2028
  • Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
  • Combination Cancer Immunotherapy Market By 15 Different Cancers
  • Insight On Clinically and Commercially Approved Cancer Immunotherapy Combinations
  • Patent, Price, and Dosage Analysis On Approved Combination Drugs
  • Global and Regional Sales Insights On Approved Combination Drugs Till 2028
  • Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
  • Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
  • Clinical Trials and Patent Insight By Company, Country, Indication, and Phase


Key Topics Covered:

1. Combination Cancer Immunotherapy - New Era in Cancer Research

2. Need for Combination Cancer Immunotherapy

3. Clinically & Commercially Approved Combination Cancer Immunotherapy

4. Global Combination Cancer Immunotherapy Market Size & Trend Analysis

5. Global Combination Cancer Immunotherapy Market Size & Trend Analysis by Indication

6. Global Combination Cancer Immunotherapy Market Size & Trend Analysis by Region

7. Approved Immune Checkpoint Inhibitor in Combination Cancer Immunotherapy - Clinical & Commercial Insights

8. Approved Antibody Drug Conjugate in Combination Cancer Immunotherapy - Clinical & Commercial Insights

9. Approved Monoclonal Antibodies in Combination Cancer Immunotherapy - Clinical & Commercial Insights

10. Combination Cancer Immunotherapy Clinical Trials Overview

11. Combination Cancer Immunotherapy Clinical Trials & Patent Insight by Company, Country, Indication & Phase

12. Marketed Combination Cancer Immunotherapy Clinical & Patent Insight by Company, Country, & Indication

13. Combination Strategies to Enhance Immune Checkpoint Inhibitors Efficacy

14. Combination of Therapeutic Antibodies in Clinical Oncology

15. Engaging Cancer Vaccines in Combination Therapy

16. Antibody Drug Conjugate in Combination Therapy


17. Combination Therapy with Car T Cell Therapy

18. Oncolytic Virus Combination Therapy

19. Competitive Landscape

For more information about this report visit

View source version on


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2022.

PUB: 06/23/2022 06:05 AM/DISC: 06/23/2022 06:06 AM